Biotech Values

[RockRat]

I should follow Teva more closely than I do. To this point, my regime consists of putting it on my ticker and reading what you and idos have to say. Why stop now?

Have you or idos or anyone else looked into their IP in the FoB/biosimilar/complex mixture space? I'm guessing much of it would lie in the name of recent acquisitions. I'll start doing the legwork if no one else has or wants to, but the more the merrier.

Regards, RockRat